Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927768 · ClinicalTrials.gov registry record
Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP)
A clinical trial of Breast Cancer, sponsored by NYU Langone Health.
- Active
- Registry status
- 264
- Enrollment target
- 1
- Study location
NCT03927768: Active study of Breast Cancer, sponsored by NYU Langone Health.
NCT03927768 is a study of Breast Cancer that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 264 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03927768, a study of Breast Cancer, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- 264 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to use a magnetic resonance imaging (MRI) sequence called golden-angle radial compressed sensing and parallel imaging (GRASP) as a noninvasive and fast way to measure the wash-in contrast (dye) in the breast. MRI uses a strong magnetic field and radio waves to create images of structures in the body. The goal is to determine if benign and malignant breast lesions have different patterns of contrast wash in. This study will ask woman planning to undergo a clinical breast MRI with contrast (dye) as part of their standard care.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Predictive Model
- DIAGNOSTIC_TEST Breast Imagers
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2026-08-31 |
What the registry record for NCT03927768 still lists
NCT03927768 is an observational study that tracks outcomes without assigning an intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Predictive Model is the first listed.
NCT03927768 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03927768 about?
NCT03927768 is a clinical study titled "Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP)". The purpose of this study is to use a magnetic resonance imaging (MRI) sequence called golden-angle radial compressed sensing and parallel imaging (GRASP) as a noninvasive and fast way to measure the wash-in contrast (dye) in the breast. MRI uses a strong magnetic field and radio waves to create ima...
What is the current status of trial NCT03927768?
This trial is currently active not recruiting. The enrollment target is 264 participants. The study started on 2018-07-31. Estimated completion is 2026-08-31.
What conditions does trial NCT03927768 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03927768?
The interventions under investigation include: Predictive Model (DIAGNOSTIC_TEST), Breast Imagers (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03927768?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03927768 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03927768's enrollment target sits among peer trials
264 311th of 1224 higher than 914 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI